TargetMol

WHI-P154

Product Code:
 
TAR-T1985
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1985-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1985-5mg5mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1985-1mL1 mL * 10 mM (in DMSO)£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1985-10mg10mg£141.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1985-25mg25mg£219.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1985-50mg50mg£351.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1985-100mg100mg£526.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
WHI-P154 is a potent JAK3 inhibitor.
CAS:
211555-04-3
Formula:
C16H14BrN3O3
Molecular Weight:
376.21
Pathway:
Angiogenesis; Tyrosine Kinase/Adaptors; Chromatin/Epigenetic; Stem Cells; JAK/STAT signaling; Apoptosis
Purity:
0.996
SMILES:
COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC
Target:
Apoptosis; EGFR; VEGFR; JAK; Src

Documents

References

1. Changelian PS,Blood, 2008, 111(4), 2155-2157. 2. Narla RK, et al. Clin Cancer Res, 1998, 4(10), 2463-2471. 3. Narla RK, et al. Clin Cancer Res, 1998, 4(6), 1405-1414.